Table 1.
Description of the Articles Included in the Final Analysis
| Study, Year | Marker | Method | No. of Patients | Patient Type | Chemotherapy | Outcome Measured |
|---|---|---|---|---|---|---|
| Chae 200914 | P53 | IHC | 135 | TNBC | A | RFS, RR=5.4 95% CI [1.4–20.8], p=0.013 |
| Bae 201815 | P53 | IHC | 1088 | TNBC | AC vs AC-D vs FAC vs CMF | 10-year DFS p=0.036 |
| Lee 201816 | P53 | IHC | 678 | TNBC | A | 10-year DFS |
| Xu 201717 | P53 | IHC | 253 | TNBC | A | DFS, HR=0.68, 95% CI [0.22–2.11], p=0.55 |
| Abdel-Fatah 201322 | Bcl-2 | IHC | 600 | TNBC | A vs CMF | Five-year DFS, HR=0.61, 95% CI [0.44–0.84], p=0.003 |
| Choi 201423 | Bcl-2 | IHC | 492 | Non-basal-like | A | DFS, HR=4.479, 95% CI [1.743–11.51], p=0.002 |
| Bouchalova 201524 | Bcl-2 | IHC | 187 | TNBC | A | RFS, HR=3.73, 95% CI [1.474–9.445], p=0.005 |
| West 201531 | TIL | IHC | 255 | ER- | A | DFS, HR=0.25, 95% CI [0.09–0.66], p=0.0056 |
| Ali 201427 | TIL | IHC | 1684 | ER- | A-CMF vs CMF | BCSS, HR=0.60, 95% CI [0.37–0.96], p=0.039 |
| Dieci 201532 | TIL | H&E | 781 | ER- | A vs no CHT | OS, HR p=0.5 |
| Pruneri 201533 | TIL | H&E | 897 | TNBC | AC+CMF vs CMF | OS, HR=0.60, 95% CI [0.48–0.76], p=0.016 |
| Loi 201334 | TIL | H&E | 256 | ER- | A | RFS, HR=0.30, 95% CI [0.11–0.81], p=0.018 |
Abbreviations: A, anthracycline-based chemotherapy; AC, doxorubicin cyclophosphamide; AC-D, doxorubicin cyclophosphamide followed by docetaxel; CMF, cyclophosphamide methotrexate 5-fluorouracil; DFS, disease-free survival; ER-, oestrogen receptor-negative; FAC, 5-fluorouracil doxorubicin cyclophosphamide; HR, hazard ratio; H&E, haematoxylin and eosin; IHC, immunohistochemistry; OS, overall survival; RR, relative risk; RFS, relapse-free survival; TIL, tumor-infiltrating lymphocyte; TNBC, triple-negative breast cancer.